

Cryofocus Medtech (Shanghai) Co., Ltd. 康澧生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代號: 6922)

April 30, 2025

Dear registered shareholder(s),

Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

With reference to the notification letter dated March 14, 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Cryofocus Medtech (Shanghai) Co., Ltd. (the "Company") is writing to remind you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.cryofocus.com and the HKEXnews website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Company shall despatch to you by electronic means or by post the Actionable Corporate Communications (Note). The Company has not received your email address for the electronic dissemination of Corporate Communications. To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Company's H Share Registrar (the "H Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the H Share Registrar, the Company will send the Actionable Corporate Communications in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete the enclosed Reply Form and send it to the H Share Registrar or send an email to cryofocus.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Please be reminded that provision of your correct and effective contact details (including email address and mailing address) to the Company and /or the H Share Registrar is critically important, and any mistakes in such details may result in failure of delivery of the Company's Corporate Communications and/or Actionable Corporate Communications to you timely in the future.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

> By order of the Board Cryofocus Medtech (Shanghai) Co., Ltd. Mr. LI Kejian Chairman of the Board

Actionable Corporate Communication is any corporate communication that seeks instructions from the Company's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

以電子方式發布公司通訊安排的提示信函

根據日期為 2024 年 3 月 14 日有關「以電子方式發布公司通訊之安排」之通知信函所述,康灃生物科技(上海)股份有限公司(「公司」)謹此提醒 閣 下,公司已採用以電子方式發布公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將 要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及(如適用)其中期報告摘 要; (c) 會議通知; (d) 上市文件; (e) 通函; 和 (f) 委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.cryofocus.com 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。

徵集電子聯絡資料

根據香港聯合交易所有限公司證券上市規則第 2.07A 條,公司須向 閣下以電子方式或者郵寄方式寄送可供採取行動的公司通訊^(網註)。公司尚未收到 閣下就接收公司通訊提供電子郵件地址。為確保及時收到最新的公司通訊,公司建議 閣下透過掃描本函隨附之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者, 閣下也可以簽署回條並交回公司的 H 股證券登記處(「**H 股證券登記處**」)香港中央證券登記有限公 司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。如果公司沒有收到 閣下的有效電子郵件地址,直至 H 股證券登記處收到 閣下有效的電 子郵件地址前,公司未來將以印刷本形式發送可供採取行動的公司通訊。

閣下希望收取日後公司通訊之印刷本,請填妥隨附之回條並交予 H 股證券登記處或發送電子郵件至 cryofocus.ecom@computershare.com.hk, 並註 閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取日後公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效,此後將過 朋 期。

公司謹此提醒 閣下,向公司及/或 H 股證券登記處提供 閣下正確及有效的聯系方式(包括電子郵箱及聯系地址等)至關重要,任何資料錯誤可能導 閣下無法及時接收公司發布的公司通訊及/或可供採取行動的公司通訊(視實際情況而定)。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)期間致電H股證券登記處(852)2862 8688 查詢。

> 承董事會命 康灃生物科技(上海)股份有限公司 董事會主席 李克儉先生

REPLY FORM 回條			
To: Computershare Hong Kong Investor Service (The "H Share Registrar") 17M Floor, Hopewell Centre 183 Queen's Road East, Wan Chai, Hong H	((香	香港中央證券登記有限公司 「H 股證券登記處」) 香港灣仔皇后大道東 183 號 क 和中心 17M 樓	
(Please <u>choose ONLY ONE</u> of the options below) (請 <u>從以下選項中只選擇其中一項)</u>			
Communications (Note 3) of your personalized QR cod 選項1: 掃瞄 閣下專屬二維碼提發布可供採取行動的未來	 供 閣下之電子郵件地址,以接收公司	ation by scanning 通過電子方式	e
company (the "Company") via elect	ronic dissemination 的電子郵件地址・以確保收到以下上市公司(「 Name of the listed company Cryofocus Medt	Corporate Communications ^(Note 3) of the following lister 公司」) 通過電子方式發布可供採取行動的未來公司通 上市公司名稱: ech (Shanghai) Co., Ltd. 上海) 股份有限公司	
Email address 電郵地址: (Notes 3 / 附註 3)			_
from the receipt date of instruction. (Note 5) (Please	e mark "" in the below box if applicable)	n and noted that this instruction is valid only for one yea 年內有效。 (<i>剛註 5</i>) (如適用·請在以下方格內劃上「✓」	
English Version 英文版本	Chinese Version 中文版本	English and Chinese Versions 英文及中区	文版本
Signature(s): ^(Notes 1) 簽名: ^(附註 1)	Contact number: 聯絡電話號碼:	Date: 日期:	
講清楚模妥 關下之所有資料,如屬蒙名股東,則太回條須由 2. Any Reply Form with no signature or otherwise incorrectly comp 任何回條若未有簽署或在其他方面填寫不正確,則本回條將會 3. If the Company does not receive a functional email address in y Corporate Communication that seeks instructions from the Comp	leted will be void. 作廢。 our reply, the Company will send the Actionable Corporate Commu amy's securities holders on how they wish to exercise their rights or 1	nications in printed form in the future. Actionable Corporate Communicatio	

地方で来、北京に1982年1971年代 Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a issing adocument; (e) a circular; and (f) a proxy form. 除計分析學 10回過程/指於 20回過程/指於 20回過程/指述 20回過程/推定 20回過程/正述 20回過

- 1 (f) you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

如 関下通過二維語。電影 | 回線及/或其他方式提供多於一個的電子郵件地址、只有 関下最後提供的電子郵件地址將會被用於登記。

5. If you mark "√" in the box in Option 3, no email address will be registered and Corporate Communications* in printed form will be received.

如 関下在銀頁 3 方格内劃上 "✓" 號,將不會有電子郵件地址被登記,惟會收到公司通訊。你已知解析。

"Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
本聲明中所指的「個人資料」與香港法例第 486 章 《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵養相同。
Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a volunty basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

周下於本回條所提供的個人資料無用於(包括但不限於)有關公司以電子方式發布公司通訊及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。閣下是自願向本公司提供個人資料。若 閣下未能提供足夠資料・本公司可能無法處理 閣下在本回條上所述的指示及/或要求。
Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the H Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
公司可就任何所說即的用途或在法例規定的情况下、海、閣下的個人資料投資或時務经公司的附屬公司、H 股證券登記處、分/或其他公司或團體・並將在適單期間保留該等個人資料作核實及紀錄用途。
You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data whold be in writing, by mail to the Hong Kong privacy Officer & Computershare, com. hk,閣下有權根據(私隱條例)的條文直開及或修改 閣下的個人資料。任何該等直開及或修改 個人資料的要求均須以書面方式郵寄至 H 股證券登記處(地址為香港灣仔皇后大道東 183 號合和中心 17M 樣)向香港灣

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

(iii)

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form. 為免存疑·在本回條上的任何額外指示·公司將不予處理。

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回此回條時·請將郵寄標籤剪貼於信封上。 如在本港投寄· 閣下無需支付郵費或貼上郵票。